Summary. The influence of moderate and low insulin antibody levels on insulin absorption and plasma free insulin profiles is uncertain. Two groups of six C-peptide negative diabetic patients, one with low (3.8 + 0.8 g/l) and one with moderate (16.4__+ 2.0 ~tg/1) serum insulin antibody levels, were studied. Subjects were given 0.3 U/kg neutral human or acid bovine soluble insulin subcutaneously in random order before breakfast on separate days. Moderate antibody levels significantly blunted the rise in plasma free insulin that followed injection of the human and bovine insulins (p < 0.05). The rise in blood glucose after breakfast was significantly greater in patients with moderate antibody levels (p < 0.05) and more marked following the bovine than the human insulin (p < 0.05). Plasma free insulin, blood glucose and 3-hydroxybutyrate profiles suggest that acid bovine soluble insulin has a significantly more protracted action than neutral human insulin.
Insulin binding antibodies at high titre may cause insulin resistance [1, 2] . They may also prolong the action of injected insulin but such an effect has only been convincingly demonstrated during artificially induced severe insulin deficiency [3] [4] [5] . It is not known whether the more moderate levels of insulin antibodies found in the majority of insulin treated diabetic patients significantly affect the pharmacokinetics of insulin therapy. This could be of particular importance when attempting to mimic meal-time insulin secretory patterns. We have therefore examined the effect of moderate levels of insulin antibodies on the absorption and action of human and bovine soluble insulins.
Subjects and methods

Subjects
Two groups of six Type 1 (insulin-dependent) diabetic patients were studied: one group had serum insulin binding capacity for porcine and bovine insulins below 10 Ix/l, whilst the second group had binding above 10 Ix/1 ( Table 1 ). The groups were matched for age, duration of diabetes, insulin dose and body mass index (kg/m2).
Informed consent was given by patients and the study was approved by the Newcastle upon Tyne Health Authority Ethical Committee.
Protocol
To deplete residual subcutaneous insulin depots, patients were treated with short acting insulin alone for 24 h before the study, the last dose being given at 22.00 hours. At 08.00 hours on the day of study, patients were given either 0.3 U/kg highly purified human neutral soluble insulin (Human Actrapid, Novo Industri, Bagsvaerd, Denmark) or bovine acid soluble (Wellcome Medical Division, Crewe, UK) in , random order. The study was repeated with the other insulin preparation approximately I week later.
All injections were given into the anterior abdominal wall 10 cm lateral to the umbilicus using a 12.7 mm needle inserted vertically to the hilt by one physician. Patients ate their normal breakfast and lunch at 08.15 and 12.00 hours respectively (Table 1) , and remained at rest in a chair throughout the study with the injection site covered by their normal indoor clothing. Before the study a polyethylene cannula was inserted into a forearm vein and its patency maintained by flushing with physiological saline. Two baseline blood samples were drawn, and blood taken every 15 min for 2 h, and every 30 rain until 8 h. Blood for estimation of glucose, lactate, pyruvate, glycerol, alanine and 3-hydroxybutyrate was deproteinised immediately in perchloric acid (0.5 mol/1) and assayed by fluorimetric techniques [6] . Plasma for measurement of free insulin was separated by centrifugation for 2 min and antibodies precipitated immediately with polyethylene glycol [7] . Extracts were stored at -20 ~ and measured by radioimmunoassay [8] . Human insulin was used as standard, and cross reactivity with bovine insulin was 100%. A serum sample was drawn on the first day of study for measurement of insulin binding capactiy by an immunochemical method [9] , using human, porcine and bovine insulin as ligands. All patients had undetectable serum C-peptide levels (< 0.02 nmol/1) 90 rain following breakfast and normal plasma creatinine concentrations. SOL = Bovine acid soluble insulin purified by recrystaUization only; ISO = bovine isophane insulin; ACT = porcine neutral soluble insulin, highly purified; MONO = porcine lente insulin, highly purified
Statistical analysis
Results are expressed as mean + SEM. The areas under the free insulin and metabolic curves were calculated trapezoidally. Analysis was by Students paired or unpaired t-test or by Spearman's rank correlation unless otherwise stated. To avoid errors due to comparison of repeated measures over time, statistical tests were performed on areas under the free insulin or metabolite curves. Where a significant difference was found differences at individual time points have also been shown in the figures. A computerised curve fitting program was used to describe the mean plasma free insulin profiles. A satisfactory fit was obtained using one rising and one falling exponential, with a lag phase before insulin was detectable [10] .
Results
Insufin antibody concentrations
Serum insulin binding capacities for each patient are shown in Table 1 . Binding capacities were almost identical for each of the three insulin species tested except in patient 12 who had the highest binding capacity and whose serum showed greater affinity for bovine than porcine or human insulins.
Effect of insulin antibody concentration
Moderate levels of insulin antibodies blunted the rise in plasma free insulin levels following subcutaneous injection of both neutral human and acid bovine insulins (Fig. 1) . The areas under the plasma free insulin curves were significantly greater (p < 0.05) in patients with low antibodies for the first and second hours after human insulin and the first hour after bovine insulin. There was a significant negative correlation between the insulin antibody level of each patient and the area under the plasma free insulin curve in the first hour after injection (r = -0.63. Spearman's rs = -0.58, p < 0.05) (Fig. 2) . As intermediate-acting insulin had been withheld the previous evening patients were insulin deficient and blood glucose levels were high at the beginning of the study (12.1 _+ 1.3 mmol/1 moderate antibody group, 18.7 _+ 1.4 low antibody group). However, the rise in blood glucose after breakfast was greater in the group with moderate antibody levels than in the group with' low antibody levels (Fig.3) , the incremental area under the blood glucose curve being significantly greater (p < 0.05) in the first hour after injection of bovine insulin. Free insulin profiles were similar in the low and moderate antibody groups from 2 h after injection until the end of the study (Fig. 1) . However the computer calculated absorption rate suggest a slightly longer half life in patients with moderate antibody levels (87 versus 75 min). The rise in blood glucose concentration following lunch was similar in the groups with low and moderate antibodies during treatment with either insulin (Fig.3) , as was the rate of rise in 3-hydroxybutyrate which occurred toward the end of the study as free insulin levels declined (Fig. 4) .
Effect of insulin species and preparation
The rise in plasma free insulin concentration from baseline was more rapid with neutral human than with acid bovine insulin but this was not statistically significant. However the rise in blood glucose in response to breakfast was significantly less following the human insulin than the bovine insulin (p < 0.05 in the first hour after injection).
Plasma free insulin levels were sustained at higher levels following injection of acid bovine insulin than neutral human insulin. The area under the plasma free insulin curve was significantly greater 4-8 h after injection of the bovine insulin than after the human insulin (p < 0.01). The calculated absorption rate, once steady state had been established, corresponded to a half life of 62 min for human and 92 rain for bovine insulin. Blood glucose levels correspondingly rose less after lunch with the bovine than with the human insulin (p<0.05). Blood 3-hydroxybutyrate levels remained significantly lower between 5 and 8 h after acid bovine insulin injection than after neutral human insulin (p < 0.05). There was no significant difference in blood lactate, pyruvate, glycerol or alanine profiles. 
Discussion
The results suggest that moderate levels of circulating insulin binding antibodies are associated with a delay in the rise of plasma insulin concentrations and the onset of action of both neutral human and acid bovine insulins (Figs. 1-3) . From this study it is not possible to determine whether this is due to delay in the onset of absorption from the subcutaneous tissue or to the binding of insulin by antibodies after absorption into the circulation. However assuming that extracellular fluid comprises 20% of body weight, and that lgG concentration in the extravascular component is about 60% of that in serum, one may calculate that in our patients with moderate antibody levels the total antibody pool could, under maximal conditions, bind 3-8 units of insulin and thus could exert considerable influence on the dynamics of insulin action.
In order to mimic the normal meal-time insulin secretory pattern, the pre-prandial insulin injection should have a rapid onset of action, and insulin activity should return to base line in the post-absorptive state. In this study we found that differences in blood glucose following breakfast persisted well beyond the observed difference in free insulin levels. This suggests that the timing of the onset of insulin action to meals is of critical importance. In this respect the choice of injection site is important as absorption from the abdominal wall, the site chosen for this study, is more rapid than from the arm or leg [11, 12] . In addition administration of insulin thirty minutes before breakfast may significantly reduce the post-prandial peak in blood glucose [13] . By adjusting the time of the pre-prandial insulin injection it may be possible to minimise the small difference in the onset of action we have found between the human and bovine insulin preparations. It is unlikely, however, to compensate for the more prolonged blunting of absorption seen in our patients with moderate antibody levels, as peak plasma free insulin levels were not achieved until 2 h after injection (Fig. 1) .
Several studies [3] [4] [5] have suggested that insulin antibodies may prolong insulin action, with speculation that they may act as a buffer gradually releasing 'free' insulin to the circulation. We did not find that moderate levels of antibodies, when compared with low levels, significantly prolonged the action of human or bovine insulin over the eight hours of study. This discrepancy is most likely explained by the differing conditions of study. Whilst we examined the absorption of subcutaneously injected soluble insulin, the earlier studies [3] [4] [5] examined the role of antibodies during acute insulin deprivation induced by cessation of intravenous insulin infusion. If antibodies do play a useful role in maintaining background insulin levels this may be of greatest importance in the latter part of the night when free insulin levels are in decline with consequent deterioration in metabolic control [14] . In our study, when no intermediate acting insulin had been given the previous day, this effect was evident. The group of patients with moderate antibody levels had significantly lower fasting levels of 3-hydroxybutyrate (Fig.4 ) and blood glucose (12.1 + 1.3 versus 18.7 +__ 1.4 mmol/l, p < 0.05). This finding should however be interpreted with caution. The study was designed to assess the effect of antibodies on the meal-time action of short-acting insulin and it would be inappropriate to extrapolate these findings to overnight control with longer acting insulin preparations. In addition more patients (4 of 6) in the moderate antibody group had received acid bovine insulin the evening before study, and we have shown that the bovine soluble insulin had a more protracted action irrespective of antibody levels.
Moderate levels of insulin binding antibodies thus markedly blunt the onset of action of short acting insulins. We did not find that insulin antibodies significantly extended the action of subcutaneous injected short acting insulin but as the study was not designed to assess total duration of action such an effect may have been missed.
